Rao K, et al. - Authors prepared a model of prostate-specific antigen (PSA) costs that could be used by payers and healthcare systems to inform cost considerations under a range of different scenarios. For groups of men ages 50-54, 55-69, and 70+ years were included. Considering constrained financial resources and national pressure to decrease use of clinically unnecessary PSA-based prostate cancer screening, by focusing on the downstream costs disproportionately associated with screening men 70 and older cost savings could be attained.